Thermal ablation as an alternative to liver transplantation for hepatocellular carcinoma with clinically significant portal hypertension: propensity score matching study

• Published in: Frontiers in oncology Vol. 13; p. 1103347
• Main Authors: Long, Yinglin, Yang, Zhou, Zeng, Qingjing, Liu, Zhongqi, Xu, Erjiao, He, Xuqi, Yuan, Lianxiong, Fu, Binsheng, Li, Kai
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 26.06.2023
• Subjects: hepatocellular carcinoma; liver transplantation; Oncology; portal hypertension; propensity score matching; thermal ablation; propensity score matching; portal hypertension; thermal ablation; hepatocellular carcinoma; liver transplantation
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1103347

The objectives were to investigate the safety and efficacy of thermal ablation as an alternative to liver transplantation for hepatocellular carcinoma patients with clinically significant portal hypertension (CSPH). From July 2016 to September 2019, hepatocellular carcinoma patients with CSPH treated by liver transplantation (N=37) or thermal ablation (N=114) were enrolled. Cumulative intrahepatic recurrence, overall survival and major complications were compared by propensity score matching. In the two matched groups, the 1-, 2-, and 3-year intrahepatic recurrence rates for the ablation group (22.3%, 50.0%, and 50.0%, respectively) were significantly higher than those for the transplantation group (4.5%, 4.5%, and 4.5%, respectively) (P=0.016). The 1-, 2-, and 3-year overall survival rates were comparable between the two groups [96.1%, 88.7%, and 88.7%, respectively (ablation group) . 84.6%, 76.2%, and 76.2%, respectively (transplantation group)] (P=0.07). The major complication rate for the ablation group [4.8% (3/62)] was significantly lower than that for the transplantation group [36.0% (9/25)] (P<0.001). Thermal ablation is a safe and effective alternative for hepatocellular carcinoma patients with CSPH.